Xenon Pharmaceuticals Inc. (XENE) News
Filter XENE News Items
XENE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest XENE News From Around the Web
Below are the latest news stories about Xenon Pharmaceuticals Inc that investors may wish to consider to help them evaluate XENE as an investment opportunity.
Xenon Pharmaceuticals to Participate in Upcoming Investor ConferencesBURNABY, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that members of its executive management team will present a corporate overview and participate in the following virtual investor conferences: 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 10:15 am ET. The live webcast of the fireside chat can be accessed here.2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 3:00 pm ET. The live webcast of the company presentation can be accessed here. Details on company presentations and the links to webcasts can be found on the “Investors” section of Xenon’s website at http://investor.xenon-pharma.com. When available, we... |
Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder (MDD)U.S. FDA IND acceptance and IRB approval in place for investigator-sponsored trial, expected to be initiated in the second quarter of 2021BURNABY, British Columbia, March 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced a collaboration with the Icahn School of Medicine at Mount Sinai (Mount Sinai) to facilitate an investigator-sponsored Phase 2 proof-of-concept, randomized, parallel-arm, placebo-controlled clinical trial of XEN1101 for the treatment of major depressive disorder (MDD) and anhedonia, which is an inability to feel pleasure. The principal investigator and sponsor of the Investigational New Drug (IND) application for the study is Dr. James W. Murrough, MD, PhD, Associate Professor of Psychiatry... |
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Tops Revenue EstimatesXenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 15.00% and 47.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock? |
Recap: Xenon Pharmaceuticals Q4 EarningsShares of Xenon Pharmaceuticals (NASDAQ:XENE) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 17.07% over the past year to ($0.34), which beat the estimate of ($0.40). Revenue of $5,150,000 up by 54.70% from the same period last year, which beat the estimate of $3,220,000. Looking Ahead Xenon Pharmaceuticals hasn't issued any earnings guidance for the time being. Revenue guidance hasn't been issued by the company for now. Details Of The Call Date: Mar 01, 2021 View more earnings on XENE Time: 04:30 PM ET Webcast URL: https://edge.media-server.com/mmc/p/xocwzofr Technicals 52-week high: $20.73 52-week low: $7.00 Price action over last quarter: Up 63.35% Company Overview Xenon Pharmaceuticals Inc is a clinical-stage b... |
Xenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate UpdateXEN1101 Phase 2b “X-TOLE” Clinical Trial in Adult Focal Epilepsy on Track for Topline Data in Third Quarter of 2021 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, March 01, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the year ended December 31, 2020 and provided a corporate update. Dr. Simon Pimstone, Xenon’s Chief Executive Officer, said, “With two of our most advanced proprietary product candidates – XEN1101 and XEN496 – currently in Phase 2 and Phase 3 clinical trials, as well as a number of earlier stage clinical and non-clinical epilepsy assets in development, we believe Xenon is advancing one of the most robust epilepsy pipelines in the biopharmaceutical indus... |
Xenon Pharmaceuticals, Inc. to Host Earnings CallNEW YORK, NY / ACCESSWIRE / March 1, 2021 / Xenon Pharmaceuticals, Inc. (NASDAQ:XENE) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 1, 2021 at 4:30 PM Eastern Time. |
GW Pharma Soars To Record High On Jazz's $7.2 Billion Takeover DealJazz Pharmaceuticals agreed to buy GW Pharmaceuticals for $7.2 billion on Wednesday — sending GWPH stock to a record high. The deal values GWPH stock at a wealthy premium. |
Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021Simon Pimstone to Assume New Role as Executive Chair and Ian Mortimer to be Named Chief Executive Officer at Annual Meeting of Shareholders in June 2021 Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy on Track for Third Quarter of 2021 Phase 3 XEN496 “EPIK” Clinical Trial Initiated in Patients with KCNQ2-DEE, a Rare Orphan Pediatric DiseaseBURNABY, British Columbia, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined its key milestone opportunities and plans for a leadership transition in 2021, with all changes anticipated to take effect in June 2021 at the time of the Company’s annual meeting of shareholders. As part of the leadership transition, Dr. Simon Pimstone, X... |
BidaskClub Downgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Strong SellXenon Pharmaceuticals (NASDAQ:XENE) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Thursday, BidAskClub reports. Other research analysts have also issued research reports about the company. SVB Leerink began coverage on Xenon Pharmaceuticals in a research report on Friday, […] |
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Expected to Announce Quarterly Sales of $10.33 MillionAnalysts predict that Xenon Pharmaceuticals Inc. (NASDAQ:XENE) will report sales of $10.33 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Xenon Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $3.20 million and the highest estimate coming in at $22.44 million. Xenon Pharmaceuticals posted sales of $3.50 […] |